|
|
Prof Alastair Thompson speaks to ecancer.tv a meeting on breast cancer at NCRI 2010. This meeting will look at the role of pathologists, basic scientists, clinicians and surgeons in a truly multidisciplinary approach to cancer care. Prof Thompson discusses the research he carries out in Dundee and the clinical trials he supervises. These studies include the IBIS I and II trials looking at the prevention of breast cancer or the prevention of recurrence or progression in DCIS (ductal carcinoma in situ) breast cancer. The IBIS-I study revealed that tamoxifen reduces the incidence of breast cancer by one third in high risk women but this was associated with some serious side effects. Prof Thompson speaks about this trial and explains how positive results must be balanced against the side effects and any reduction in patient quality of life.
|
|
Video Length: 0
Date Found: January 11, 2011
Date Produced:
|
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
 www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
 www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
 www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|